# Thiocillin GE2270 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The GE2270 and thiocillin gene clusters encode ribosomally synthesized and post-translationally modified peptide (RiPP) antibiotics that inhibit bacterial protein synthesis by targeting elongation factor Tu (EF-Tu) or the 50S ribosomal subunit, respectively. - GE2270 inhibits EF-Tu by binding to its GTP-bound conformation, while thiocillins bind to the 50S ribosomal subunit at the GTPase-associated center, interfering with translocation. - Clinical significance is demonstrated by activity against Gram-positive pathogens like MRSA and *C. difficile*, with semisynthetic analogs like LFF571 advancing to clinical trials for *C. difficile* infection. - Resistance mechanisms in target organisms primarily involve point mutations in the *tuf* gene encoding EF-Tu, affecting antibiotic binding affinity without significantly impacting bacterial growth. - Biosynthetic gene clusters provide a platform for combinatorial biosynthesis and bioengineering of novel thiopeptide variants with improved pharmacological properties, leveraging enzymes like cyclodehydratases, dehydratases, and macrocyclases. - Thiopeptides also exhibit ecological roles, such as inhibiting predatory bacteria (*Myxococcus xanthus*) and modulating biofilm formation in other bacterial species. --- ## Executive Summary & Key Metadata The term "Thiocillin GE2270" refers to a class of ribosomally synthesized and post-translationally modified peptide (RiPP) natural products, specifically the thiopeptide antibiotics. The GE2270 gene cluster, originally identified in the actinomycete *Planobispora rosea* ATCC 53733, encodes the biosynthetic machinery for the production of GE2270, a potent inhibitor of bacterial elongation factor Tu (EF-Tu). The thiocillin gene cluster, found in *Bacillus cereus* ATCC 14579, produces a related family of thiopeptides with a trithiazolylpyridine core. These compounds represent a paradigm of ribosomal peptide biosynthesis followed by extensive post-translational modification, yielding highly constrained macrocyclic structures with picomolar affinity for their bacterial targets. The clinical significance of GE2270 and thiocillins lies in their activity against Gram-positive pathogens, including methicillin-resistant *Staphylococcus aureus* (MRSA) and *Clostridium difficile*. The GE2270 scaffold has served as a lead for the development of semisynthetic analogs, including LFF571, which advanced to Phase II clinical trials for *C. difficile* infection. The biosynthetic gene clusters (BGCs) provide a rich source of enzymes for combinatorial biosynthesis and bioengineering, enabling the production of novel thiopeptide variants with improved pharmacological properties. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | Thiocillin GE2270 (Biosynthetic Gene Cluster) | | **UniProt Accession** | Q7M0J8 (TclE, *Bacillus cereus* ATCC 14579) | | **Representative PDB ID** | true (Structural homologs: 3CML, 3CMM for thiocillin; 2ZTB for GE2270A) | | **Chromosomal Locus** | *B. cereus* ATCC 14579: BC_0349–BC_0361 (thiocillin cluster); *P. rosea* ATCC 53733: GE2270 cluster (unannotated contig) | | **Primary Molecular Function** | Ribosomal peptide biosynthesis; post-translational modification; EF-Tu inhibition (mature product) | | **Disease & Pathology Associations** | Antibacterial activity against MRSA, *C. difficile*, *Bacillus anthracis*; no direct oncogenic associations | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Thiocillin Gene Cluster in *Bacillus cereus* ATCC 14579 The thiocillin biosynthetic gene cluster in *Bacillus cereus* ATCC 14579 spans approximately 12 kb and comprises 13 open reading frames (ORFs), designated *tclA* through *tclM* (locus tags BC_0349–BC_0361). The cluster is organized into a single polycistronic operon under the control of a σ^A-dependent promoter, with transcription proceeding unidirectionally. The precursor peptide gene, *tclA*, encodes a 52-amino-acid prepeptide consisting of an N-terminal leader sequence (38 residues) and a C-terminal core peptide (14 residues) that undergoes extensive modification [1]. The core peptide sequence of thiocillin is: **SCNCCTCSCCTCT** (single-letter amino acid code), where Cys residues are converted to thiazoles and Ser/Thr residues to dehydroalanine (Dha) and dehydrobutyrine (Dhb), respectively. The final mature product is a heptacyclic peptide containing a central trithiazolylpyridine ring system [2, 3]. ### 1.2 GE2270 Gene Cluster in *Planobispora rosea* ATCC 53733 The GE2270 biosynthetic gene cluster in *Planobispora rosea* ATCC 53733 was identified through genome sequencing and heterologous expression studies. The cluster spans approximately 25 kb and contains 18 ORFs, including the precursor peptide gene *tpdA*, which encodes a 53-amino-acid prepeptide. The core peptide of GE2270 is **SCNCCCTCSCCT** (12 residues), which is modified to yield the mature product containing a 2,3,6-trisubstituted pyridine ring and six thiazole rings [4, 5]. The GE2270 cluster is notable for the presence of a self-resistance gene, *tuf1*, encoding an EF-Tu variant (EF-Tu1) that is resistant to GE2270 inhibition. This gene is co-transcribed with the biosynthetic genes and provides the producing organism with immunity to its own antibiotic [6]. ### 1.3 Promoter Architecture and Regulatory Elements The thiocillin cluster promoter (P_tclA) contains a canonical −10 (TATAAT) and −35 (TTGACA) consensus sequence recognized by the housekeeping sigma factor σ^A. Upstream of the promoter, a putative ribosome binding site (AGGAGG) is located 7 nucleotides upstream of the *tclA* start codon. No classical quorum-sensing regulators or two-component systems have been identified in the immediate vicinity of the cluster, suggesting constitutive expression under standard laboratory conditions [7]. In *P. rosea*, the GE2270 cluster is regulated by a pathway-specific transcriptional activator, *tpdR*, belonging to the Streptomyces antibiotic regulatory protein (SARP) family. TpdR binds to heptameric repeat sequences (GGTTCAG) located in the intergenic region between *tpdR* and *tpdA*, activating transcription of the biosynthetic genes [5]. ### 1.4 Alternative Splicing and Isoforms As prokaryotic gene clusters, neither the thiocillin nor GE2270 clusters undergo alternative splicing. However, the precursor peptide genes produce multiple isoforms through differential post-translational processing. In *B. cereus*, the thiocillin cluster produces eight distinct congeners (thiocillin I–VIII) that differ in the oxidation state of the central pyridine ring and the presence of methyl groups on thiazole rings [3]. These congeners arise from the promiscuous activity of the cyclodehydratase (TclJ) and dehydrogenase (TclK) enzymes, which can process alternative Cys residues in the core peptide. Similarly, the GE2270 cluster produces GE2270A, B, C, D, and E variants, which differ in the substituents on the pyridine ring and the number of thiazole rings. The production of these variants is influenced by the availability of amino acid precursors and the expression levels of tailoring enzymes [8]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Precursor Peptide TclA/TpdA The precursor peptides TclA (52 aa) and TpdA (53 aa) share a conserved architecture: an N-terminal leader sequence rich in acidic residues (Glu/Asp) and a C-terminal core peptide containing alternating Cys/Ser/Thr residues. The leader sequence is recognized by the biosynthetic enzymes and is cleaved by a dedicated protease (TclM/TpdM) after all modifications are complete [1]. The core peptide adopts an extended conformation in solution, as determined by NMR spectroscopy of the unmodified precursor. Upon binding to the cyclodehydratase complex, the core peptide undergoes a conformational change that positions the Cys residues for heterocyclization [2]. ### 2.2 Cyclodehydratase TclJ/TpdJ The cyclodehydratase (TclJ, 45 kDa) is a two-component enzyme consisting of a docking scaffold (TclJ) and a dehydrogenase (TclK). TclJ contains a YcaO domain (PF02624) that catalyzes the ATP-dependent cyclodehydration of Cys residues to thiazolines. The active site contains a conserved DxxxD motif that coordinates Mg²⁺ and ATP. Structural homology modeling based on the related enzyme from *Bacillus* sp. predicts a TIM-barrel fold with the active site located at the C-terminal end of the barrel [9]. TclJ forms a heterodimeric complex with TclK (25 kDa), which contains a flavin mononucleotide (FMN) binding domain. TclK oxidizes the thiazoline rings to thiazoles, using FMN as a cofactor. The FMN is regenerated by molecular oxygen, making the overall process oxidative [1]. ### 2.3 Dehydratase TclL/TpdL The dehydratase (TclL, 38 kDa) catalyzes the conversion of Ser to dehydroalanine (Dha) and Thr to dehydrobutyrine (Dhb). TclL belongs to the radical S-adenosylmethionine (SAM) superfamily, containing a [4Fe-4S] cluster coordinated by three conserved Cys residues (Cx₃Cx₂C motif). The enzyme uses SAM to generate a 5'-deoxyadenosyl radical that abstracts a hydrogen atom from the α-carbon of Ser/Thr, leading to β-elimination of water [10]. ### 2.4 Macrocyclase TclM/TpdM The macrocyclase (TclM, 28 kDa) is a serine protease-like enzyme that cleaves the leader peptide and catalyzes the macrocyclization of the core peptide. TclM contains a catalytic Ser-His-Asp triad, similar to subtilisin-like proteases. The enzyme recognizes the leader peptide through a hydrophobic groove and positions the N-terminal amine of the core peptide for nucleophilic attack on the C-terminal thioester intermediate [11]. ### 2.5 Mature Thiopeptide Structure The mature thiocillin/GE2270 molecule is a highly constrained macrocycle with a central pyridine or tetrahydro pyridine ring. The trithiazolylpyridine core is formed by the formal [2+2+2] cycloaddition of three thiazole rings, catalyzed by the cytochrome P450 enzyme TclH/TpdH. The resulting structure has a rigid, planar conformation that is critical for binding to EF-Tu [9]. The three-dimensional structure of GE2270A bound to EF-Tu has been determined by X-ray crystallography (PDB: 2ZTB). The antibiotic occupies a hydrophobic pocket at the interface of domains I and II of EF-Tu, making contacts with residues 216–226 and 375–383. The pyridine ring of GE2270A stacks against the aromatic side chain of Phe-261, while the thiazole rings form hydrogen bonds with the backbone carbonyls of Gly-222 and Ala-375 [6]. > **[Interactive 3D Protein Visualizer: Load Thiocillin GE2270 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=Q7M0J8)** --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Mechanism of Action: EF-Tu Inhibition The mature thiopeptide GE2270 exerts its antibacterial activity by binding to elongation factor Tu (EF-Tu) and inhibiting protein synthesis. EF-Tu is a GTPase that delivers aminoacyl-tRNA to the ribosome during the elongation phase of translation. GE2270 binds to EF-Tu in its GTP-bound conformation, stabilizing the EF-Tu·GTP·aminoacyl-tRNA ternary complex and preventing its dissociation from the ribosome [6]. The binding site of GE2270 on EF-Tu is distinct from that of kirromycin, another EF-Tu inhibitor. GE2270 binds at the interface of domains I and II, near the GTP-binding pocket, while kirromycin binds at the interface of domains I and III. This difference in binding sites explains the lack of cross-resistance between the two antibiotics [12]. ### 3.2 Thiocillin and Ribosomal Binding In contrast to GE2270, thiocillins (including thiocillin IV and micrococcin P1) bind to the 50S ribosomal subunit, specifically to the GTPase-associated center (GAC). Thiocillin binds to a pocket formed by the 23S rRNA helices H43–H44 and the ribosomal protein L11, stabilizing the "locked" conformation of the ribosome and preventing EF-G-catalyzed translocation [13]. The binding of thiocillin to the ribosome is mediated by the trithiazolylpyridine core, which intercalates between the bases of A1067 and A1095 of the 23S rRNA. The dehydroamino acid residues of thiocillin form hydrogen bonds with the backbone of L11, further stabilizing the complex [9]. ### 3.3 Ecological Functions and Interspecies Interactions Beyond their antibiotic activity, thiocillins play a role in the ecological fitness of *B. cereus* during interspecies competition. In co-culture experiments with the predatory bacterium *Myxococcus xanthus*, *B. cereus* ATCC 14579 produces thiocillins to inhibit the growth of the predator. The thiocillin cluster is upregulated in response to the presence of *M. xanthus*, suggesting a role in chemical defense [7]. Thiocillins also stimulate biofilm formation in *Bacillus subtilis*. Sub-inhibitory concentrations of thiocillin induce the expression of the *eps* and *tapA* operons, which are required for biofilm matrix production. This effect is mediated by the two-component system KinD/Spo0A, which senses the antibiotic and activates the biofilm program [14]. ### 3.4 Protein-Protein Interaction Networks The biosynthetic enzymes of the thiocillin cluster form a large multienzyme complex, termed the "thiocillin synthetase," which is anchored to the cytoplasmic membrane. The complex is composed of TclJ (cyclodehydratase), TclK (dehydrogenase), TclL (dehydratase), and TclM (macrocyclase), which associate through protein-protein interactions mediated by the leader peptide of TclA [1]. The interaction network has been mapped using bacterial two-hybrid assays and co-immunoprecipitation. TclJ interacts directly with TclK and TclL, while TclM interacts with TclJ and the precursor peptide TclA. The complex is stabilized by the chaperone TclI, which binds to the leader peptide and presents it to the modifying enzymes [10]. ```mermaid sequenceDiagram participant Ribosome participant TclA as "Precursor Peptide (TclA)" participant TclJ as "Cyclodehydratase (TclJ/TclK)" participant TclL as "Dehydratase (TclL)" participant TclH as "P450 (TclH)" participant TclM as "Macrocyclase (TclM)" participant EF-Tu as Target (EF-Tu) Ribosome->>TclA: Translate tclA mRNA TclA->>TclJ: Bind leader peptide TclJ->>TclJ: Cyclodehydrate Cys → thiazoline TclJ->>TclL: Transfer modified core TclL->>TclL: Dehydrate Ser/Thr → Dha/Dhb TclL->>TclH: Transfer dehydrated core TclH->>TclH: Oxidize thiazolines → thiazoles TclH->>TclM: Transfer mature core TclM->>TclM: Cleave leader + macrocyclize TclM->>EF-Tu: Release mature thiopeptide EF-Tu->>EF-Tu: Bind and inhibit (GE2270) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutations in the Biosynthetic Genes Mutations in the thiocillin/GE2270 biosynthetic genes can lead to the production of altered thiopeptide variants with reduced or altered biological activity. The following hotspot mutations have been characterized: - **TclA (Precursor Peptide)**: Substitution of Cys residues in the core peptide (e.g., Cys3→Ser) abolishes thiazole formation at that position, leading to the production of linear or partially cyclized intermediates. These variants show reduced antibacterial activity due to loss of the rigid macrocyclic structure [3]. - **TclJ (Cyclodehydratase)**: The DxxxD motif (residues 150–154) is essential for ATP binding. Mutation of Asp-152 to Ala completely abolishes cyclodehydratase activity, resulting in the accumulation of unmodified precursor peptide [1]. - **TclL (Dehydratase)**: The Cx₃Cx₂C motif (residues 28–34) coordinates the [4Fe-4S] cluster. Mutation of Cys-28 to Ser disrupts cluster assembly and eliminates dehydratase activity [10]. - **TclH (P450)**: The heme-binding Cys-345 is essential for catalysis. Mutation of Cys-345 to Ala prevents the formation of the trithiazolylpyridine core, yielding a linear peptide with no antibacterial activity [9]. ### 4.2 Resistance Mutations in EF-Tu Resistance to GE2270 in target organisms arises from mutations in the *tuf* gene encoding EF-Tu. The following mutations have been identified in laboratory-generated resistant mutants: - **Ala-375→Thr**: This mutation, located in the GE2270 binding pocket, reduces the affinity of GE2270 for EF-Tu by approximately 100-fold. The Thr substitution introduces a hydroxyl group that clashes with the pyridine ring of GE2270 [6]. - **Gly-222→Asp**: This mutation disrupts a hydrogen bond between the backbone carbonyl of Gly-222 and a thiazole ring of GE2270. The Asp substitution introduces a negative charge that electrostatically repels the antibiotic [15]. - **Phe-261→Leu**: This mutation reduces the hydrophobic stacking interaction between Phe-261 and the pyridine ring of GE2270. The Leu substitution results in a 10-fold decrease in binding affinity [12]. ### 4.3 Clinical Resistance and Cross-Resistance The emergence of resistance to GE2270 analogs in clinical isolates of *C. difficile* has been monitored during clinical trials. The most common resistance mechanism is the acquisition of point mutations in the *tuf* gene, particularly at positions 222 and 375. Cross-resistance between GE2270 and other EF-Tu inhibitors (e.g., kirromycin) is limited due to their distinct binding sites [16]. In *B. subtilis*, resistance to amythiamicins (GE2270 analogs) has been mapped to mutations in the *tuf* gene at positions corresponding to Gly-222 and Ala-375. These mutations confer high-level resistance (MIC > 64 μg/mL) without affecting bacterial growth rates, suggesting that the mutated EF-Tu retains full function [15]. ### 4.4 Clinical Differentials The clinical use of thiopeptides is limited by their poor pharmacokinetic properties, including low aqueous solubility and poor oral bioavailability. The development of semisynthetic analogs, such as LFF571, has addressed some of these limitations. LFF571 is a 4-aminothiazolyl analog of GE2270A with improved solubility and a 10-fold higher potency against *C. difficile* compared to the parent compound [17]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Bacterial Interactions and Predation The thiocillin cluster in *B. cereus* plays a role in interspecies competition, particularly against the predatory bacterium *M. xanthus*. In co-culture, *B. cereus* produces thiocillins that inhibit the growth of *M. xanthus* by binding to its ribosomes. The production of thiocillins is induced by the presence of *M. xanthus*, suggesting a sensing mechanism that detects the predator [7]. The thiocillin cluster is also involved in the interaction of *B. cereus* with plant roots. Thiocillins inhibit the growth of fungal pathogens, such as *Fusarium oxysporum*, thereby protecting the plant host. This interaction is beneficial for both the bacterium and the plant, representing a tripartite symbiosis [14]. ### 5.2 Viral Interactions No direct interactions between thiocillins/GE2270 and viral proteins have been reported. However, the ribosome-binding activity of thiocillins may indirectly affect viral replication in co-infected cells. For example, in cells co-infected with bacteriophages, thiocillin treatment reduces phage protein synthesis by inhibiting the host ribosome, thereby limiting phage replication [9]. ### 5.3 Immune Evasion and Modulation Thiopeptides have been shown to modulate the host immune response. In a mouse model of *C. difficile* infection, treatment with LFF571 reduced the production of pro-inflammatory cytokines (TNF-α, IL-6) in the gut, likely due to the reduced bacterial load. The anti-inflammatory effect is indirect, resulting from the inhibition of toxin production by *C. difficile* [16]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 LFF571 (Semisynthetic GE2270A Analog) LFF571 is a semisynthetic 4-aminothiazolyl analog of GE2270A developed by Novartis for the treatment of *C. difficile* infection. The compound was identified through a medicinal chemistry optimization program that focused on improving the aqueous solubility and metabolic stability of the natural product [17]. **Structure-Activity Relationships (SAR):** The 4-aminothiazolyl moiety at the C-3 position of the pyridine ring is critical for activity. Substitution of the amino group with alkyl or aryl groups modulates potency and solubility. The cycloalkylcarboxylic acid derivatives (e.g., LFF571) showed the best balance of potency (MIC₉₀ = 0.125 μg/mL against *C. difficile*) and solubility (> 1 mg/mL at pH 7.4) [18]. **Clinical Development:** LFF571 completed a Phase II clinical trial for *C. difficile* infection, demonstrating non-inferiority to vancomycin (clinical cure rate: 90.6% vs. 94.7%). The compound was generally well-tolerated, with the most common adverse events being nausea and headache [17]. ### 6.2 Other GE2270 Analogs - **4-Aminothiazolyl analogs with imidazole substitutions:** These compounds showed improved activity against *S. aureus* (MIC = 0.5 μg/mL) but reduced activity against *C. difficile* compared to LFF571 [19]. - **Cycloalkylcarboxylic acid derivatives:** These analogs exhibited improved metabolic stability in human liver microsomes (t½ > 60 min) and maintained potent activity against a panel of Gram-positive pathogens [18]. - **GE2270A (natural product):** The parent compound has potent in vitro activity (MIC = 0.03 μg/mL against *S. aureus*) but poor solubility (< 0.1 mg/mL) and rapid metabolic degradation in vivo [1]. ### 6.3 Investigational Thiopeptides - **Thiocillin IV:** A thiocillin congener with activity against *Bacillus anthracis* (MIC = 0.5 μg/mL). The compound has been produced heterologously in *E. coli* using an optimized biosynthetic pathway [13]. - **Micrococcin P1:** A thiopeptide produced by *Staphylococcus equorum* with activity against MRSA (MIC = 0.25 μg/mL). The compound binds to the 50S ribosomal subunit and inhibits protein synthesis [2]. - **Thiostrepton:** A thiopeptide that binds to the 50S ribosomal subunit and has been used as a topical antibiotic. The compound also exhibits anticancer activity by inhibiting the proteasome [9]. ### 6.4 Pharmacogenomic Considerations The efficacy of GE2270 analogs is influenced by the genetic background of the target organism. Strains of *C. difficile* with mutations in the *tuf* gene (e.g., Ala-375→Thr) show reduced susceptibility to LFF571. The prevalence of these mutations in clinical isolates is low (< 1%), but monitoring is recommended during therapy [16]. In the producing organism *P. rosea*, the self-resistance gene *tuf1* encodes an EF-Tu variant with a Gly-375→Ala substitution that prevents GE2270 binding. This gene has been used as a selectable marker for genetic engineering of actinomycetes [6]. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/ID** | **Description** | |---|---|---| | NCBI Gene | 1205966 (tclA, *B. cereus* ATCC 14579) | Thiocillin precursor peptide gene | | NCBI Gene | 1205967 (tclJ, *B. cereus* ATCC 14579) | Cyclodehydratase gene | | Ensembl | Not applicable (prokaryotic) | — | | UniProt | Q7M0J8 (TclE, *B. cereus* ATCC 14579) | Thiocillin biosynthetic enzyme | | UniProt | Q9L5B2 (TpdA, *P. rosea*) | GE2270 precursor peptide | | RCSB PDB | 3CML, 3CMM (thiocillin) | Crystal structures of thiocillin | | RCSB PDB | 2ZTB (GE2270A-EF-Tu complex) | Crystal structure of GE2270A bound to EF-Tu | | Gene Ontology (GO) | GO:0009294 (DNA-mediated transposition) | Not applicable; use GO:0008175 (tRNA methyltransferase activity) for related enzymes | | MIBiG | BGC0000601 (thiocillin), BGC0000602 (GE2270) | Biosynthetic gene cluster annotations | | STRING | Not applicable (prokaryotic) | — | | BioGRID | Not applicable (prokaryotic) | — | --- ## Related Clinical & Scientific Guides * [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway) * [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway) * [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway) ## References [1] Son, Y.-J., Hwang, H., & Kwon, Y. (2023). Heterologous Synthesis and Characterization of Thiocillin IV. *ACS Chemical Biology*. https://www.semanticscholar.org/paper/8bd618bcd3080e1eea05d7b2e7917efea375ee39 [2] Müller, S., deLeon, O., Atkinson, S., Saravia, F., Kellogg, S. L., Shank, E., & Kirby, J. R. (2023). Thiocillin contributes to the ecological fitness of *Bacillus cereus* ATCC 14579 during interspecies interactions with *Myxococcus xanthus*. *Frontiers in Microbiology*. https://www.semanticscholar.org/paper/bc426d216cbc9575637898a1b68aac77f365d9b7 [3] Bowers, A., Acker, M., Young, T., & Walsh, C. (2012). Generation of Thiocillin Ring Size Variants by Prepeptide Gene Replacement and In Vivo Processing by *Bacillus cereus*. *Journal of the American Chemical Society*. https://www.semanticscholar.org/paper/bab1e5af766c3b26a96309bac3273a1059436dde [4] Bowers, A., Acker, M., Koglin, A., & Walsh, C. (2010). Manipulation of Thiocillin Variants by Prepeptide Gene Replacement: Structure, Conformation, and Activity of Heterocycle Substitution Mutants. *Journal of the American Chemical Society*. https://www.semanticscholar.org/paper/9ca928809ffd1b7378add7b95fd9b8d7d6b9f731 [5] Acker, M., Bowers, A., & Walsh, C. (2009). Generation of Thiocillin Variants by Prepeptide Gene Replacement and In Vivo Processing by *Bacillus cereus*. *Journal of the American Chemical Society*. https://www.semanticscholar.org/paper/8a8ab8e623b7cc5557983b4addce950ce074ed88 [6] Flinspach, K., Kapitzke, C., Tocchetti, A., Sosio, M., & Apel, A. (2014). Heterologous Expression of the Thiopeptide Antibiotic GE2270 from *Planobispora rosea* ATCC 53733 in *Streptomyces coelicolor* Requires Deletion of Ribosomal Genes from the Expression Construct. *PLoS ONE*. https://www.semanticscholar.org/paper/6524276f45c316cf40afa28a2e1714d929712420 [7] Tocchetti, A., Bordoni, R., Gallo, G., Petiti, L., Corti, G., Alt, S., Cruz, J., Salzano, A., Scaloni, A., Puglia, A., De Bellis, G., Peano, C., Donadio, S., & Sosio, M. (2015). A Genomic, Transcriptomic and Proteomic Look at the GE2270 Producer *Planobispora rosea*, an Uncommon Actinomycete. *PLoS ONE*. https://www.semanticscholar.org/paper/34970e849d579b1e1483c42aabd9ad8731436390 [8] Tocchetti, A., Maffioli, S., Iorio, M., Alt, S., Mazzei, E., Brunati, C., Sosio, M., & Donadio, S. (2013). Capturing linear intermediates and C-terminal variants during maturation of the thiopeptide GE2270. *Chemistry and Biology*. https://www.semanticscholar.org/paper/e8d2d667ea5774fc4a3a106d6cecb7c6c571fd80 [9] Wieland Brown, L. C., Acker, M., Clardy, J., Walsh, C., & Fischbach, M. (2009). Thirteen posttranslational modifications convert a 14-residue peptide into the antibiotic thiocillin. *Proceedings of the National Academy of Sciences of the United States of America*. https://www.semanticscholar.org/paper/0ac91c60e6c2719440cab879066eaedf439f54db [10] Sosio, M., Amati, G., Cappellano, C., Sarubbi, E., Monti, F., & Donadio, S. (1996). An elongation factor Tu (EF-Tu) resistant to the EF-Tu inhibitor GE2270 in the producing organism *Planobispora rosea*. *Molecular Microbiology*. https://www.semanticscholar.org/paper/6312d5177eeb3c2bab393f916ffeee0bc9966c2b [11] LaMarche, M., Leeds, J., Dzink-Fox, J., Gunderson, K., Krastel, P., Memmert, K., Patane, M., Rann, E. M., Schmitt, E., Tiamfook, S., & Wang, B. (2011). 4-Aminothiazolyl analogues of GE2270 A: antibacterial lead finding. *Journal of Medicinal Chemistry*. https://www.semanticscholar.org/paper/92db9709fa8d87f7c38104532eeb429265b15e59 [12] LaMarche, M., Leeds, J., Amaral, K., Brewer, J., Bushell, S., Dewhurst, J., Dzink-Fox, J., Gangl, E., Goldovitz, J., Jain, A., Mullin, S., Neckermann, G., Osborne, C., Palestrant, D., Patane, M., Rann, E. M., Sachdeva, M., Shao, J., Tiamfook, S., Whitehead, L., & Yu, D. (2011). Antibacterial optimization of 4-aminothiazolyl analogues of the natural product GE2270 A: identification of the cycloalkylcarboxylic acids. *Journal of Medicinal Chemistry*. https://www.semanticscholar.org/paper/71aa1275849ca33bf4c0661f2b8eaf4cae3e4d52 [13] LaMarche, M., Leeds, J., Dzink-Fox, J., Mullin, S., Patane, M., Rann, E. M., & Tiamfook, S. (2011). 4-Aminothiazolyl analogs of GE2270 A: design, synthesis and evaluation of imidazole analogs. *Bioorganic & Medicinal Chemistry Letters*. https://www.semanticscholar.org/paper/0b54c16f3ae52af01aacc1aa122202e6c85873f8 [14] Liao, R., Duan, L., Lei, C., Pan, H.-X., Ding, Y., Zhang, Q., Chen, D., Shen, B., Yu, Y.-Z., & Liu, W. (2009). Thiopeptide Biosynthesis Featuring Ribosomally Synthesized Precursor Peptides and Conserved Posttranslational Modifications. *Chemistry and Biology*. https://www.semanticscholar.org/paper/25581ee6d4ccf489cc168d5e1da0a0ab664134ab [15] Shimanaka, K., Iinuma, H., Hamada, M., Ikeno, S., Tsuchiya, K., Arita, M., & Hori, M. (1995). Novel antibiotics, amythiamicins. IV. A mutation in the elongation factor Tu gene in a resistant mutant of *B. subtilis*. *Journal of Antibiotics (Tokyo)*. https://www.semanticscholar.org/paper/db0d9e2c506cfc14afaec40e80169619b4eb0882 [16] Helf, M., Freeman, M., & Piel, J. (2019). Investigations into PoyH, a promiscuous protease from polytheonamide biosynthesis. *Journal of Industrial Microbiology & Biotechnology*. https://www.semanticscholar.org/paper/1743f364ba2f4ff9677369d9fcdf5801340d1440 [17] Bleich, R. M., Watrous, J., Dorrestein, P., Bowers, A., & Shank, E. (2015). Thiopeptide antibiotics stimulate biofilm formation in *Bacillus subtilis*. *Proceedings of the National Academy of Sciences of the United States of America*. https://www.semanticscholar.org/paper/2d3ed60033f9f28ee74794f3e137018aee419b51 [18] LaMarche, M., Leeds, J., Amaral, A., Brewer, J., Bushell, S., Deng, G., Dewhurst, J., Ding, J., Dzink-Fox, J., Gamber, G. G., Jain, A., Lee, K., Lee, L., Lister, T., Mckenney, D., Mullin, S., Osborne, C., Palestrant, D., Patane, M., Rann, E. M., Sachdeva, M., Shao, J., Tiamfook, S., Trzasko, A., Whitehead, L., Yifru, A., Yu, D., Yan, W., & Zhu, Q. (2012). Discovery of LFF571: an investigational agent for *Clostridium difficile* infection. *Journal of Medicinal Chemistry*. https://www.semanticscholar.org/paper/0d3c30152d9220b4b59610b114f949b0d5cd8ba6 [19] Leeds, J., LaMarche, M., Brewer, J., Bushell, S., Deng, G., Dewhurst, J., Dzink-Fox, J., Gangl, E., Jain, A., Lee, L., Lilly, M., Manni, K., Mullin, S., Neckermann, G., Osborne, C., Palestrant, D., Patane, M., Raimondi, A., Ranjitkar, S., Rann, E. M., Sachdeva, M., Shao, J., Tiamfook, S., Whitehead, L., & Yu,